Identification of major histocompatibility complex class I ligands in ovarian adenocarcinoma tumors

ABSTRACT: BACKGROUND. For developing targeted immunotherapy against ovarian adenocarcinoma, direct identification of peptides presented by major histocompatibility complex class I (HLA I) on the surface of tumor cells can be utilized.AIM. To identify ligands of HLA I of ovarian adenocarcinoma tumors. METHODS. Immunopeptidome from postoperative material of patients with ovarian adenocarcinoma were isolated using immunoaffinity chromatography and analyzed by liquid chromatography-mass spectrometry.RESULTS. Using NP-40, 5 peptides belonging to the proteins of cancer/testis antigens (CTA) were identified in the immunopeptidomes of postoperative material from patients with ovarian adenocarcinoma, 3 of which, according to the human protein atlas, are indeed not expressed in normal ovarian tissues.CONCLUSION. Immunopeptidome analysis allows the identification of peptides of CTA proteins, but a larger sample of postoperative material from patients with ovarian adenocarcinoma and experimental testing of the immunogenicity of the identified peptides are needed for further research.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Ovary, Malignant Cell

DISEASE(S): Malignant Neoplasm Of Ovary

SUBMITTER: Georgij Arapidi  

LAB HEAD: Georgij Arapidi

PROVIDER: PXD077095 | Pride | 2026-04-15

REPOSITORIES: Pride